title: Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
authors.affiliation: Institute of Liver Studies, King's College Hospital at King's College London School of Medicine, London, UK.
authors.forename: Beverley
authors.initials: B
authors.lastname: Kok
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Foxton
authors.forename: Christopher
authors.initials: C
authors.lastname: Clough
authors.forename: Debbie L
authors.initials: DL
authors.lastname: Shawcross
mesh_terms: D000368:Aged; D000641:Ammonia / Q000097:blood; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D004569:Electroencephalography; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D010641:Phenotype; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D012294:Rifamycins; D000641:Ammonia; D000078262:Rifaximin